Register for our free email digests:
Latest From Helsinn Birex Pharmaceuticals Ltd.
Two orphan medicines have been withdrawn from the evaluation process at the European Medicines Agency, one of them for recurrent nephrotic syndrome, the other for mesothelioma. Three products are undergoing a re-evaluation after an initial negative opinion from the CHMP.
Other medicines receiving positive opinions from the EU’s top scientific advisory panel after its March meeting include Helsinn’s Akynzeo for chemotherapy associated nausea and vomiting, the first 9-valent HPV vaccine, Sanofi Pasteur MSD’s Gardasil 9, and Boehringer Ingelheim’s Synjardy combination of empagliflozin and metformin.
The market for supplements sold by health care providers heats up, with firms offering practitioner-focused labeling, custom brands and products targeted to specific patient needs. As supplement use grows, more practitioners are interested in guiding patients’ choices in vitamins and other nutritionals.
- Large Molecule
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- BioVascular Inc.
- Senior Management
John Parrish, CEO
Alison J Pilgrim, MD, PhD, CMO, VP, Clin. Dev.
Eric Karpinski, VP, Bus. Dev.
- Contact Info
Phone: (858) 455-5000
12230 El Camino Real
San Diego, CA 92130
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.